Oxana Iliach is a Senior Director of Regulatory Strategy at Certara (PA, USA), a biotech company that offers comprehensive solutions for transforming and accelerating drug development. In her spare ...

Explore AI in drug discovery and its journey from promise to proof in 2025 with significant achievements and challenges faced.

Regulatory challenges have been even more top of mind than usual given recent upheaval at the FDA. BioSpace spoke to three industry experts about key issues, which include applying new artificial ...

The potential of using artificial intelligence in drug discovery and development has sparked both excitement and skepticism among scientists, investors, and the general public. Researchers have ...

With big pharma signalling interest in novel RNA-targeted approaches, the term “druggable” is being redefined as technology ...

On Dec 19, 2025, the US Food and Drug Administration (FDA) announced a major milestone by qualifying total hip bone mineral density (BMD), assessed by dual-energy X-ray absorptiometry, as a surrogate ...

Researchers have applied AI and machine learning to every stage of the drug development process. This includes identifying targets in the body, screening potential candidates, designing drug molecules ...

The emergence of AI and biosensors offers a chance to address inefficiencies in drug development.

Chemists have recently achieved a significant breakthrough by using copper to crack the toughest bond in indole, a complex organic compound. This advancement holds immense potential for accelerating ...

Carter emphasizes that women are currently serving as primary “thought leaders” in the advancement of precision medicine . In ...